PMV Pharmaceuticals (PMVP) Assets Average (2020 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Assets Average came in at $106.6 million in Q1 2026, down 41.11% YoY from $180.9 million in Q1 2025, and down 14.89% on a QoQ basis from $125.2 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Assets Average (2020 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 7 years of Assets Average data on file, last reported at $106.6 million in Q1 2026.
- Quarterly Assets Average fell 41.11% year-over-year to $106.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $106.6 million (down 41.11% YoY) and the FY2025 annual result came in at $153.9 million, down 30.58% from the prior year.
- Assets Average eased to $106.6 million in Q1 2026, from $125.2 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $323.3 million in Q1 2022 to a low of $106.6 million in Q1 2026.
- A 5-year average of $226.9 million and a median of $244.5 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average declined 4.39% — and 2026, when it plunged 41.11%.
- Tracing PMVP's Assets Average over 5 years: stood at $277.6 million in 2022, then retreated by 7.58% to $256.6 million in 2023, then slipped by 19.17% to $207.4 million in 2024, then slumped by 39.63% to $125.2 million in 2025, then slipped by 14.89% to $106.6 million in 2026.
- The last three Assets Average figures came in at $106.6 million (Q1 2026), $125.2 million (Q4 2025), and $143.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | 89.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106.56 Mn |
| Dec 31, 2025 | 125.20 Mn |
| Sep 30, 2025 | 143.35 Mn |
| Jun 30, 2025 | 161.73 Mn |
| Mar 31, 2025 | 180.95 Mn |
| Dec 31, 2024 | 207.39 Mn |
| Sep 30, 2024 | 230.52 Mn |
| Jun 30, 2024 | 237.21 Mn |
| Mar 31, 2024 | 244.51 Mn |
| Dec 31, 2023 | 256.59 Mn |
| Sep 30, 2023 | 251.62 Mn |
| Jun 30, 2023 | 248.09 Mn |
| Mar 31, 2023 | 262.13 Mn |
| Dec 31, 2022 | 277.65 Mn |
| Sep 30, 2022 | 292.77 Mn |
| Jun 30, 2022 | 307.79 Mn |
| Mar 31, 2022 | 323.29 Mn |
| Dec 31, 2021 | 337.87 Mn |
| Sep 30, 2021 | 350.04 Mn |
| Jun 30, 2021 | 355.15 Mn |